Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries

References

• Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:609–616.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–1799.
   PubMed Web of Science ®Google Scholar
• Tota JE, Chevarie-Davis M, Richardson LA, et al. Epidemiology and burden of HPV-related disease. Vol. XXX, s.l.: Elsevier Ltd; 2017.
   Google Scholar
• Forman D, de Martel C, Lacey CJ, et al. Global burben of humman papillomarirus and related diseases. Vaccine. 2012;30:F12–F23.
   PubMed Web of Science ®Google Scholar
• Hartwig S, Baldauf JJ, Dominiak-Felden G, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe. Papillomavirus Res. 2015;1:90–100.
   Web of Science ®Google Scholar
• Vardas E, Giuliano AR, Goldstone S, et al. External genital human papillomavirus prevalence and associated. J Infect Dis. 2011;203(1):58–65.
   PubMed Web of Science ®Google Scholar
• Harper D, DeMars L. HPV vaccines – a review of the first decade. Vol. 146 (1), East Broadway: Elsevier Inc. 2017. 0090–8258.
   Google Scholar
• Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. San Francisco: PLoS Med. 2006;3(5).
   Web of Science ®Google Scholar
• DeMars LR, Meza R, Harper DM. Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time? s.l.: Elsevier, Vaccine. 2018;36(33): 0264–410X.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo M, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04 adjuvanted vaccine: combined analysis of data from the costa rica vaccine trial and the PATRICIA trial. Lancet Oncol. 2015;16:1470–2045.
   Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. 9961, s.l. Lancet Onc 2014;384:2213-2227.
   Google Scholar
• WHO: Immunization,Vaccines and Biologicals database. WHO/Immunization,vaccines and biologicals database. WHO (INTERNET). [Online] 2017 June 18 [Cited 2017 Feb 28]. Available from: http://www.who.int/entity/immunization/monitoring_surveillance/VaccineIntroStatus.
   Google Scholar
• Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PRISMA 2009 Check list. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) website (INTERNET). [Online] 2015 [Cited 2018 Mar 10]. Available from: http://www.prisma-statement.org/Default.aspx
   Google Scholar
• World Bank. World Bank Open Data. World Bank Web site (INTERNET). [Online] 2018 January 1 [Cited 2018 Mar 13]. Available from: http://www.worldbank.org
   Google Scholar
• U.S. Bureau of Labor Statistics. Bureau of labor statistics: data tools: databases,tables & calculators by subject: CPI. U.S. Bureau of Labor Statistics Web site (ITERNET). [Online] 2016 January 1 [Cited 2016 Mar 14]. Available from: www.bls.gov/CPI
   Google Scholar
• WHO. WHO Cost-effectiveness thresholds. WHO (INTERNET). [Online] 2015 October 13. Available from: http://www.who.int/choice/costs/CER_thresholds/en.
   Google Scholar
• Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29:8279–8284.
   PubMed Web of Science ®Google Scholar
• Goldie S, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–615.
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781–789.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Ins. 2011;103:1373–1386.
   PubMedGoogle Scholar
• Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151:538–545.
   PubMed Web of Science ®Google Scholar
• Kim JJ. Cost effectiveness analysis of including boys in a human. BMJ. 2009;339:1–10.
   Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP, et al. Age-based programs for vaccination against HPV. Value Health. 2009;12:697–707.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Atlanta: s.n. Emerg Infect Dis. 2007;13: 28–41.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. J Natl Cancer Inst. 2008;359:821–832.
   Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244–251.
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert J, Stout N, Salomon J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100:308–320.
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–1923.
   PubMed Web of Science ®Google Scholar
• Drolet M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;114:2264–2268.
   Web of Science ®Google Scholar
• Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013;31:3863–3871.
   PubMed Web of Science ®Google Scholar
• Anonychuk A, Bauch C, Merid M, et al. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009;9:401.
   PubMed Web of Science ®Google Scholar
• Brisson M, Van De Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399–53408.
   PubMed Web of Science ®Google Scholar
• Gomez JA, Lepetic A, Demarteau N. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health. 2014;14:1–13.
   PubMed Web of Science ®Google Scholar
• Jit M, Hong CYH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337(a769):1–12.
   Google Scholar
• Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. Bjog. 2008;115(8):947–956.
   PubMed Web of Science ®Google Scholar
• Kulasingam S, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc. 2008;6:4.
   PubMedGoogle Scholar
• Zechmeister I, Blasiob BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133–5144.
   PubMed Web of Science ®Google Scholar
• Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care. 2009;25(2):161–170.
   PubMed Web of Science ®Google Scholar
• Olsen J, Jørgensen T. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Allocation. 2015;13(4):1–10.
   PubMed Web of Science ®Google Scholar
• Uusküla A, Müürsepp A, Kawai K, et al. The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia. BMC Infect Dis. 2013;13(304):1–8.
   PubMed Web of Science ®Google Scholar
• Torvinen S, Nieminen P, Lehtinen M, et al. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ. 2010;13(2):284–294.
   PubMedGoogle Scholar
• Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008;24(1):10–19.
   PubMed Web of Science ®Google Scholar
• Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2: 2–10. ISSN: 2191-1991.
   PubMedGoogle Scholar
• Vokó Z, Nagyjánosi L, Kaló Z. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health. 2012;12:2–7.
   PubMed Web of Science ®Google Scholar
• Usher C, Tilson L, Olsen J, et al. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine. 2008;26:5654–5661.
   PubMed Web of Science ®Google Scholar
• Mennini FS, Rossi PG, Palazzo F, et al. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol. 2009;112:370–376.
   PubMed Web of Science ®Google Scholar
• Haeussler K, Marcellusi A, Mennini FS, et al. Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic Bayesian methodology: the BEST II study. Value Health. 2015;18:956–968.
   PubMed Web of Science ®Google Scholar
• Westra TA, Stirbu-Wagner I, Dorsman S, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013;13:2–11.
   PubMed Web of Science ®Google Scholar
• Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011;204:377–384.
   PubMed Web of Science ®Google Scholar
• de Kok I, van Ballegooijen M, Habbema J. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101:1083–1092.
   PubMedGoogle Scholar
• Coupe VMH, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer. 2009;124:970–978.
   PubMed Web of Science ®Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health. 2010;20(4):415–421.
   PubMed Web of Science ®Google Scholar
• Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin. 2008;24:1473–1483.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine. 2007;25:6677–6691.
   PubMed Web of Science ®Google Scholar
• Vernon J, Lee VJ, Tay SK, et al. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011;11:1–11.
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Insinga RP, Yang YC, et al. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev. 2008;9:459–466.
   PubMedGoogle Scholar
• Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National cervical cancer screening program. Sex Health. 2007;4:165–175.
   PubMed Web of Science ®Google Scholar
• Blakely T, Kvizhinadze G, Karvonen T, et al. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014;32:2645–2656.
   PubMed Web of Science ®Google Scholar
• Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. s.l.: Elsevier. Vaccine. 2015;33(32):3788-3794.
   Google Scholar
• WHO. Human papillomavirus vaccines: WHO position paper. Geneva: WHO; 2017. p. 241–268.
   Google Scholar